Completely honored to discuss the global disparities of bladder cancer clinical trial availability with THE Ashish M. Kamat, MD, MBBS, President of IBCG 🌎🔬Thank you to UroToday.com & mentor Sumanta K. Pal, MD, FASCO for this opportunity. Check it out! Regina Barragan-Carrillo Daniela V. Castro Miguel Zugman

Incredible paper led by Daniela V. Castro exploring the impact of insurance status on oncologic outcomes in pts with mRCC. Journal of Clinical Oncology #OncologyAdvances

It’s been a minute! Good morning Chicago ☀️ I will be at AACR today presenting our work on CD5 cells and IO response. If you are interested in learning more, join me at Section 32/Board 26 (9-12AM PST). Appreciate the support of Sumanta K. Pal, MD, FASCO who made this possible and Marcin Kortylewski🇵🇱🇺🇦

#AACR25 In our study high baseline CD5 B cells linked to worse outcomes in mRCC patients treated with cabo/nivo. ➡️CD5+ B cells may be a prognostic biomarker—and potential target—for ICB response Thank you Sumanta K. Pal, MD, FASCO Marcin Kortylewski🇵🇱🇺🇦 Hedyeh Ebrahimi and Marice Alcantara, PhD!

What a wonderful moment - seeing @AlexisLevee get ready to take the stage to claim her ASCO Young Investigator Award! So proud of all her tremendous accomplishments as a fellow at City of Hope (she got an excellent foundation from Heather McArthur, MD, MPH, FASCO in residency - her co-mentor on this

Huge congrats to Nazli Dizman MD Anderson Cancer Center! Can affirm that all the below is true! So proud. #ASCO25

🏔️ A standing ovation at #ASCO25 for Dr. Christopher Booth and the CHALLENGE (CO.21) trial. A 3-year structured exercise program post-chemo in stage II/III colon cancer: ✅ Improved OS (HR 0.63, p=0.022) ✅ 1 life saved for every 14 patients 💬 “Exercise is no longer just a QOL

🥗 Powerful diet-focused study at #ASCO25 presented by Sara Khosrowjerdi Char, MD from CALGB/SWOG 80702: 🔹 Proinflammatory diet linked to worse OS in stage III colon cancer 🔹 Best outcomes in patients with high physical activity and anti-inflammatory diet 🔹 NSAIDs didn’t alter the

Huge congrats to Jasnoor Malhotra and #ASchlager on this important paper Eur Urol Focus reviewing HRQOL assessments in mRCC clinical trials! A timely synthesis of the strengths & gaps in current PROMs; a clear call for more patient-centered tools 👏 kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Proud of Ruchi Agarwal, a Penn undergraduate who spent her summers working with us at City of Hope. Today she presented her work with Regina Barragan-Carrillo Instituto Nacional de Cancerología on international #kidneycancer trial availability - so impressive!

Excited to share the bulk of my thesis work available online today @CancerCell. We sought to dive into the tumor microenvironment of sarcomatoid renal cell carcinomas to better understand what makes RCC tumors susceptible to immunotherapy: sciencedirect.com/science/articl… 1/n

Excited to share our new paper European Urology Oncology! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better capture HRQOL in localized & metastatic RCC, moving beyond generic instruments to what truly matters to patients Tom Powles Sumanta K. Pal, MD, FASCO sciencedirect.com/science/articl…

1/ JUST PUBLISHED at #CGC journal: Evaluating Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy 🔵Occult LN involvement occurs in 25% of pts with cN0 MIBC. 🔵LN involvement

Terrific conference that so many of my City of Hope colleagues have benefitted from - Nazli Dizman @AlexisLevee Daniela V. Castro Regina Barragan-Carrillo Hedyeh Ebrahimi - please consider attending!

🚨 Thrilled to share our new manuscript in Cancers MDPI! 🚀 We evaluated clinical & pathologic predictors for pUS at cystectomy in pts with MIBC. Huge thanks to the team at City of Hope Genitourinary Cancer Research Team @CityofHope and to incredible mentors Abhishek Tripathi Sumanta K. Pal, MD, FASCO Wesley Yip Clayton Lau

What a pleasure to work with Vitor Abreu de Góes, MD - a terrific scholar from Einstein Hospital Israelita. Impressive presentation at #ASCOQLTY25 - & so glad he connected w Paulo G Bergerot & Cristiane D Bergerot Grupo Oncoclínicas (fmr City of Hope) as well!

Thank you for the highlight, my friend! Please don’t miss a great session, covering many other biomarkers, including LAG3 and KIM-1 in ccRCC and PD-L1 expression in the context of the SUNNIFORECAST trial. Rana McKay, MD, FASCO Wenxin (Vincent) Xu Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

Great overview by Shankar Siva at #ESMO25 on the role of SABR/SBRT in oligoprogressive RCC SABR is safe, non-invasive, and allows continuation of systemic therapy without interruption Ongoing trials are actively exploring its synergy with systemic therapy UroToday.com OncoAlert

⏰Happening now! Great line-up ahead in Hall 7.1c at #ESMO25 “Optimising management of localised bladder cancer” moderated by Regina Barragan-Carrillo & Karima Oualla, MD,MSc OncoAlert OncLive.com